-transparent.png){kind=logo}
Preliminary studies indicate that somatostatin (SRIF, somatropin release inhibiting factor) can suppress exercise-induced plasma growth hormone rise in normal subjects as well as in diabetics.
Related Publications
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
July 1976,
The Journal of clinical endocrinology and metabolism,
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
July 1975,
British medical journal,
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
October 1973,
Biochemical and biophysical research communications,
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
March 1977,
Clinics in endocrinology and metabolism,
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
June 1974,
Lancet (London, England),
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
October 1974,
Molecular and cellular endocrinology,
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
January 1974,
Pharmacology, biochemistry, and behavior,
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
March 1974,
British medical journal,
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
May 1975,
Lancet (London, England),
A P Hansen, and
H Orskov, and
K Seyer-Hansen, and
K Lundbaek
January 1989,
Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College = Chung-kuo i hsueh k'o hsueh yuan, Chung-kuo hsieh ho i k'o ta hsueh hsueh pao,
